EBV Reactivation Has Linked to Multiple Sclerosis Relapse
New research shows how immune signatures in B cells precede the onset of multiple sclerosis relapses.
Updated on Oct. 9, 2026 in Stroke
Live Poll
Do you trust that recent findings on virus-linked disease triggers will improve long-term treatment outcomes?
Scientists have identified an immune signature in multiple sclerosis patients that occurs before a relapse. The findings suggest that the Epstein-Barr virus periodically reactivates within primed B cell compartments to trigger flare-ups.
Why it matters
Understanding the mechanism behind MS relapses is a critical step in developing targeted treatments. This research highlights the specific role the Epstein-Barr virus plays in the progression of the autoimmune disease.
Blood samples revealed elevated Epstein-Barr virus LMP1 transcripts in B cells prior to relapse. This immune signature shows direct overlap with multiple sclerosis genome-wide association study risk loci.
The players
Nature Medicine
This is a monthly peer-reviewed medical journal that publishes research on clinical and translational medicine.
The details
Researchers utilized longitudinal multi-omics profiling to track immune changes across different stages of the disease. They observed EBV-responsive host genes and the presence of gp350 surface protein on CD11c atypical B cells during the period immediately preceding a relapse.
Timeline
October 9, 2026: The research findings were published in Nature Medicine.
The Big Picture
This study advances the Epstein-Barr virus disease association research framework by identifying a specific relapse trigger. It provides a deeper mechanistic understanding of how viral reactivation correlates with autoimmune flare-ups.
These findings provide patients and clinicians with a better understanding of the biological events occurring before a relapse. While this is a research breakthrough, it may eventually lead to new monitoring strategies for disease activity.
The takeaway
This research confirms a long-suspected link between viral activity and the episodic nature of multiple sclerosis. Clinicians may eventually use these identified immune signatures to better predict and manage patient health trajectories.
Further reading
Learn more about the latest developments in Stroke.
Source note: This article includes information reported by Nature.
Live Poll
Do you trust that recent findings on virus-linked disease triggers will improve long-term treatment outcomes?
